A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Jun 2016.
- 01 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Dec 2014 to 1 Jun 2016.
- 10 Oct 2013 New trial record